Objective: The aim of the study was to examine treatment continuation and satisfaction over 1 year among women receiving nomegestrol acetate (NOMAC)/oestradiol (E2) combined oral contraception (COC) in real-world clinical practice. Methods: The 17b-Estradiol and Nomegestrol Acetate (BOLERO) Study is an observational, noninterventional, prospective, multicentre cohort study of premenopausal women (aged 18-50 years) who received prescription NOMAC/E2 (2.5 mg/1.5 mg) for contraception during routine clinical practice. Assessments were carried out at enrolment and at 3, 6 and 12 months. Probability of treatment continuation through 12 months (primary outcome) was examined using Kaplan-Meier survival analysis. Secondary outcomes included treatment satisfaction, menstrual cycle-related symptoms, libido and adverse events (AEs). Results: Of 298 enrolled women, 292 were evaluable. The probability of NOMAC/E2 continuation through 12 months was 73.7% (95% confidence interval [CI] 68.0%, 78.5%). Satisfaction with NOMAC/E2 increased from 56.9% (37/65) of women at initial evaluation to 89.2% (58/65) of women at 12 months. Physician ratings at 12 months showed satisfactory to very satisfactory in 84.0% (168/200) of women. Libido was not affected. Menstrual cycle-related symptoms significantly declined from enrolment (6.04 ± 4.32) to 3 months (3.25 ± 3.05) and 12 months (2.62 ± 2.74; p < .0001). Treatment-related AEs were reported by 38.7% (113/292) of women. Conclusion: The real-world experience of women receiving NOMAC/E2 indicated very good treatment continuation, high satisfaction and significantly improved menstrual cycle-related symptoms.
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Introduction
Combined oral contraception (COC) continues to be a frequently selected contraceptive method among European women [1] . The evolution in COC formulations to improve safety and tolerability has included ethinylestradiol (EE) and progestin dose reductions, development of new progestins and varied dosing regimens [2] . More recently, COC based on oestradiol (E2), structurally identical to endogenous 17b-E2, has become available [3] . Nomegestrol acetate (NOMAC)/E2 (Zoely; Teva Italia, Milan, Italy), approved by the European Medicines Agency in 2011, is the first monophasic 24/4 day COC regimen to use 17b-E2. It has been shown that E2, micronised to improve bioavailability, has weak estrogenic effects and a mild metabolic impact on estrogen-sensitive hepatic proteins [3] . NOMAC, derived from 19-norprogesterone with almost exclusive binding to the progesterone receptor, has been shown to be metabolically neutral with no androgenic, estrogenic or glucocorticoid activity and with moderate antiandrogenic activity [3] .
The efficacy of NOMAC/E2, as well as good menstrual cycle control, with shorter and lighter withdrawal bleedings and absence of withdrawal bleeding for some women, has been demonstrated in randomised, open-label, multicentre trials that compared NOMAC/E2 with a drospirenone/EE 21/7 day regimen [4, 5] . NOMAC/E2 has also been associated with reduced premenstrual and menstrual symptoms and menstrual cramping [6, 7] , as well as improved quality of life [7, 8] . NOMAC/E2 contraceptive efficacy was maintained with less stringent back-up requirements following missed pills, likely related to the long half-life of NOMAC (46 h) and the 24/4 day regimen of NOMAC/E2 [4, 5] . Consistent with this finding, contraceptive protection is not reduced if the missed NOMAC/ E2 active pill is taken <24 h late [9] . Further, compared with levonorgestrel/EE, NOMAC/E2 has demonstrated significantly less haemostatic impact (assessed via evaluation of coagulation and fibrinolysis markers), no alteration of carbohydrate metabolism (assessed using glucose tolerance and insulin resistance) and a neutral effect on lipid metabolism (assessed through levels of triglycerides and low-and high-density lipoprotein cholesterol) [10] . The potential for reduced haemostatic impact is noteworthy given the continued efforts to reduce the risk of venous thromboembolism that is moderately associated with COC treatment [10] .
NOMAC/E2 may help address an ongoing need for COC formulations that support treatment continuation, given that concerns about the use of synthetic hormones and associated side effects are frequently reported by women as reasons for COC discontinuation [11, 12] . Women have expressed a preference for COC based on natural estrogen, following contraceptive counselling, primarily because of fear of synthetic hormones or a desire for decreased bleeding associated with E2-based COC [13] . To address whether NOMAC/E2 meets these characteristics, the current study examined treatment continuation and satisfaction over 1 year among women receiving NOMAC/E2 for contraception in real-world clinical practice.
Methods

Study design and population
The 17b-Estradiol and Nomegestrol Acetate (BOLERO) Study is an observational, non-interventional, prospective, multicentre cohort study conducted in 17 centres in Italy. Eligible participants were premenopausal women aged 18-50 years, with or without prior COC use, who were prescribed NOMAC 2.5 mg/E2 1.5 mg for contraception during routine clinical practice. Contraceptive treatment selection and consent to study participation were independent decisions. Women received their prescription for NOMAC/E2 ! 1 month and <3 months prior to study enrolment. Exclusion criteria included any condition that contraindicated use of COC and age !35 years in current smokers. Women were recruited over a 15 month period and were followed for a period of 12 months (13 treatment cycles). Study assessments were carried out at enrolment and at 3, 6 and 12 months. The end-of-study final evaluation was completed before 12 months if a woman discontinued study participation early.
The study was conducted in full conformance with the principles of the Declaration of Helsinki, and fully adhered to the Guideline for Good Clinical Practice, International Conference on Harmonization Tripartite Guideline and local laws. Independent ethics committees of the participating centres approved the study protocol; women provided informed consent prior to participation in the study.
Assessments
The primary efficacy outcome was continuation of treatment, defined as the number of treatment cycles completed over 12 months and assessed using a daily diary.
Secondary outcomes included treatment satisfaction, menstrual cycle-related symptoms and libido. Treatment satisfaction was assessed with a 7 point scale ranging from 'very unsatisfactory' to 'very satisfactory' at 3, 6 and 12 months or at the final study visit. Additionally, treating physicians rated treatment satisfaction at 12 months or at the final study visit using the Clinical Global Impression (CGI) 7 point scale that ranged from 'very unsatisfactory' to 'very satisfactory'. Evaluation of menstrual cycle-related symptoms included headache, breast pain/tenderness, swelling (abdominal swelling and oedema), dysmenorrhoea and mood disturbance. Symptoms were assessed using 5 point scales ranging from 'absent' to 'serious', and the total symptom score was summed across the individual symptoms. The assessment of menstrual cycle-related symptoms at enrolment was retrospective: women were asked to assess symptoms related to their last three menstrual cycles prior to initiating NOMAC/E2. Additionally, treating physicians rated the degree of improvement in overall menstrual cycle-related characteristics and symptoms at 12 months or at the final study visit using the CGI 7 point scale that ranged from 'much worse' to 'much improved'. Level of libido was rated on a 5 point scale that ranged from 'very poor' to 'very satisfactory' at 3, 6 and 12 months or at the final study visit.
Safety was examined through reports of adverse events (AEs) from study enrolment to the final study visit. Treatment emergent AEs (TEAEs) and treatment-related AEs were assessed. Physicians rated AEs as unrelated (no reasonable possibility) or related (reasonable possibility) to treatment, and AE severity (mild/moderate/severe) and AE seriousness (yes/no). AEs were coded by MedDRA version 16.0 (www.meddra.org) and used preferred terms. Values are expressed as mean ± SD or n (%).
Data analysis
The primary outcome of continuation of NOMAC/E2 treatment was assessed using Kaplan-Meier survival analysis and is reported as the discontinuation-free probability estimate at day 365 with 95% confidence intervals (CIs). Change in the menstrual cycle-related total symptom score was examined using general linear models for repeated measures with 95% CIs. This analysis used a univariate test for within-subject effects using mixed models (Proc Mixed; SAS Institute, Cary, NC, USA) to fit models with a variety of error covariance matrices and evaluate the patterns of covariance matrices (defined as type H covariances) to satisfy the Huynh-Feldt condition, by applying a sphericity test. Adjustment to numerator and denominator degrees of freedom was used to obtain an unbiased estimate of the effects. Treatment satisfaction, CGI physician ratings and libido were examined descriptively using percentages within response categories. AEs were summarised by the percentage of women experiencing any AE and by individual AEs. Analyses included all enrolled women and were completed using SAS version 9.2 or later (SAS Institute, Cary, NC, USA). Numerical data are expressed as mean-± standard deviation (SD). For all statistical analyses, pvalues <.05 were considered significant.
Results
A total of 298 women from 17 centres were enrolled (Tables 1 and 2 
Treatment continuation
Kaplan-Meier analysis showed that the probability of NOMAC/E2 continuation from enrolment to day 365 was 73.7% (95% CI 68.0%, 78.5%; Figure 2 ). Among women with prior COC use before starting NOMAC/E2, the probability of treatment continuation to day 365 was 74.2% (95% CI 67.8%, 80.6%). Among women with no prior COC use, the probability of treatment continuation to day 365 was 70.7% (95% CI 61.5%, 78.1%).
Treatment satisfaction, menstrual cycle-related symptoms and libido
Satisfaction with NOMAC/E2 increased from 56.9% (37/65) of women at the time of initial evaluation performed Values are expressed as mean ± SD or n (%). a Multiple responses allowed. b Other reasons included: participant decision without further explanation (n ¼ 6), unknown (n ¼ 6), amenorrhoea (n ¼ 1), metrorrhagia (n ¼ 1) and dysmenorrhoea (n ¼ 1).
within 3 months of NOMAC/E2 use to 89.2% (58/65) of women at the final visit performed 12 months after initial evaluation ( Figure 3 ). Among the 28 women dissatisfied at enrolment, 92.9% (26/28) were satisfied with treatment at the final visit; only 13.5% (5/37) of those satisfied at enrolment were dissatisfied at the final visit. Additionally, physician ratings of each woman's treatment satisfaction at 12 months showed unsatisfactory in 7.0% (14/200), indifferent in 9.0% (18/200) and satisfactory to very satisfactory in 84.0% (168/200). Women reported a significant improvement in menstrual cycle-related symptoms (p < .0001) during NOMAC/E2 treatment ( Table 3 ). The menstrual cycle-related total symptom rating declined from 6.04 ± 4.32 at enrolment to 3.25 ± 3.05 at 3 months of NOMAC/E2 treatment, and further declined to 2.62 ± 2.74 at 12 months. Women with prior COC use before initiating NOMAC/E2 and women without prior COC use were similar in their report of menstrual cycle-related symptoms at enrolment and decline in symptoms over 12 months with NOMAC/E2 ( Figure 1 . Participant disposition. Reasons for discontinuation of NOMAC/E2 included treatment-related AEs, poor compliance, dissatisfaction and decision to change contraceptive method. Discontinuation of NOMAC/E2 that was not treatment-related included no longer needed contraception, scheduled surgery and desire for pregnancy. symptom score, p < .0001. Total symptom score is the sum of the ratings of the individual symptoms on a 5 point scale ranging from absent to serious for menstrual cycle-related headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance.
Libido was not affected by NOMAC/E2 treatment. Unsatisfactory libido was reported by 14.7% of women at the enrolment visit and by 10.7% after a follow-up of 12 months (Figure 4 ).
Safety
TEAEs were reported by 44.2% (129/292) of women; 38.7% (113/292) of women experienced AEs that were considered possibly treatment-related. The most common treatmentrelated AEs (reported by 2-13% of women) were metrorrhagia, amenorrhoea, headache, abdominal distension, breast discomfort, mood changes and acne (Table 4) . Less than 2% of women reported weight gain (n ¼ 4; 1.4%) or decreased libido (n ¼ 2; 0.7%). Two serious AEs were reported, including primary mediastinal large B cell lymphoma, considered unrelated to treatment, and a pregnancy. The pregnancy occurred in a 22-year-old single woman with a BMI 24.2 kg/m 2 . She reported that her previous use of COC had been interrupted for headache. No information was available on her use of NOMAC/E2 or the pregnancy outcome. Treatment discontinuation due to AEs occurred in 31/ 292 (10.6%) women. The AEs most commonly associated with treatment discontinuation were headache (drug withdrawal headache, n ¼ 1; other headache or migraine, n ¼ 11) and mood changes (n ¼ 7). Treatment discontinuation due to metrorrhagia occurred in 3/292 (1.0%) of women, suggesting that most women with metrorrhagia were experiencing breakthrough spotting or light bleeding.
Discussion
Findings and interpretation
Efficacious and tolerable COC that supports treatment continuation, satisfaction and adherence is essential to prevent COC discontinuation and potential subsequent use of less effective contraceptive methods [11] , and further reduce the number of unplanned pregnancies. NOMAC/E2 may be an especially good match for women who prefer COC based on natural estrogen. In the current study, women who selected NOMAC/E2 for contraception during routine clinical practice showed high probability of treatment continuation from study enrolment to 12 months.
Differences and similarities in relation to other studies
Most women reported satisfaction with NOMAC/E2 throughout the study. This was consistent with the significant improvement in menstrual cycle-related symptoms reported by women and their physicians. The significant improvement in menstrual cycle-related symptoms, including headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance, observed at 3 months and with continued improvement to 12 months, is consistent with previous studies examining NOMAC/E2 [6, 7] . The high NOMAC/E2 continuation rate is also consistent with the low frequency of AEs resulting in treatment discontinuation. The report of satisfactory libido by most women in the current study is in line with the report of improved sexual function among women who chose to switch to NOMAC/E2 from another COC due to dissatisfaction with sexual desire during their previous treatment [14] . The amenorrhoea experienced by some women is similar to findings from previous NOMAC/E2 studies and is likely related to the long half-life of NOMAC and 24/4 day NOMAC/E2 regimen [4, 5] .
Concern about side effects is frequently reported by women as their primary reason for COC dissatisfaction and discontinuation, including concern about side effects related to EE and consideration of switching contraception to reduce exposure to hormones [11, 12, [15] [16] [17] . In a realworld clinical practice study of women in Spain, 21.1% of women discontinued COC use for treatment-related reasons, including poor cycle control, side effects, method failure and 'other' [18] . In our study of women receiving NOMAC/E2 in routine clinical practice, treatment-related reasons for discontinuation, including AEs or other reasons, was lower at 17.5% of women. Non-treatment-related discontinuation in our study, in 5.8% of women, was similar to a real-world clinical practice study of COC continuation in Spain that reported 6.6% (including women with pregnancy desire and change in sexual habits), whereas our participants lost to follow-up were fewer (8.2% vs 19.3%) [18] . The continuation rate of NOMAC/E2 in our study appears to be comparable to, or higher than, COC continuation rates reported in other population-based cohorts or real-world studies [16] [17] [18] [19] .
Strengths and weaknesses of the study
Strengths of this study include the real-world examination of a large sample of women receiving NOMAC/E2 for [19, 20] . In our study, women received their prescription for NOMAC/E2 during routine clinical care and study participants independently answered questions about their experience with NOMAC/E2. Because participants were not encouraged to continue NOMAC/E2 or provided with any financial or other support, the effect of study participation on treatment continuation was probably minimal. Real-world prospective observational studies of clinical practice outcomes also complement findings from retrospective health claims database studies. Database studies provide important information on the use of contraceptive treatment across large populations of women [21] ; however, many relevant variables, such as change in menstrual cycle-related symptoms, are not captured in these databases. Such clinical information, necessary to understanding the reasons underlying continuation of COC, as well as potential targets for contraceptive counselling, can be gathered in real-world observational studies.
The current observational study excluded women receiving other COC formulations, which prevented direct comparisons among types of COC. The study findings should be considered preliminary and warrant further comparative investigation of COC continuation and satisfaction among women who select NOMAC/E2 vs EE-based COC.
Conclusion
NOMAC/E2 is the first monophasic 24/4 day COC regimen based on E2, which is structurally identical to the endogenous 17b-E2 that is naturally produced by the ovaries. Previous studies have indicated a preference for COC based on natural estrogen among some women, and improved quality of life among women who switched to COC based on natural estrogen. In our study, the real-world experience of women who were prescribed NOMAC/E2 during routine clinical practice indicated very good treatment continuation and high satisfaction with treatment through 12 months. The non-contraceptive benefits of NOMAC/E2 included significantly improved menstrual cycle-related symptoms of headache, breast pain/tenderness, swelling, dysmenorrhoea and mood disturbance. Our findings provide further evidence that NOMAC/E2 COC meets contraceptive and noncontraceptive needs and supports treatment continuation among women seeking contraception based on natural estrogen.
